Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 756 of 5804
-
New balloon method may improve stent success in Rock-Hard arteries
Disease control CompletedSeverely calcified coronary stenoses are difficult to treat with percutaneous coronary intervention (PCI) using current techniques and there is little specific evidence on how to best treat these cases. It is hypothesized that balloon lithoplasty is superior to conventional ballo…
Phase: NA • Sponsor: Herlev and Gentofte Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New trial matches cancer drugs to tumor DNA for advanced patients
Disease control Recruiting nowThis trial is a multicenter, open-label, biology driven, phase II study using a sequential Bayesian design, aiming to assess the efficacy and safety of different Matched Targeted Therapy (MTT) in independent and parallel cohorts of treatment. Patients will be assigned to a treat…
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug cocktail shows promise in slowing rare sarcoma
Disease control OngoingThis is an open-label, non-randomized, single-institution, single arm Phase II study conducted using a Simon two-stage design with an additional safety lead-in. The overall objective is to determine the efficacy of combination doxorubicin with dual checkpoint blockade with anti-C…
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for older blood cancer patients: smarter transplants aim to cut relapse
Disease control OngoingTreatment options for older adults with Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) are limited. Although stem cell transplantation remains one of the most effective treatments it is associated with severe side effects which have until recently prevented its use in old…
Phase: PHASE2, PHASE3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Cheaper drug could rival expensive biologic for rare artery disease
Disease control OngoingGiant-cell arteritis (GCA) is the most frequent vasculitis after 50 years. It is characterized by a granulomatous inflammation of the wall of large vessels, involving especially the aorta and extra-cranial branches of the external carotid, with vascular remodelling leading to isc…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Gentler lung treatment may help preterm babies avoid breathing tubes
Disease control CompletedThis study is being conducted to determine whether prophylactic administration of surfactant by the Less Invasive Surfactant Administration (LISA) method reduces the need for mechanical ventilation in the first 72 hours of life when compared to early Continuous Positive Airway Pr…
Phase: NA • Sponsor: Sharp HealthCare • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New master trial aims to speed up cancer treatments for kids
Disease control Recruiting nowThe main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New surgery aims to stop lymphedema before it starts
Disease control OngoingThe researchers are doing this study to see if having immediate lymphatic reconstruction after axillary lymph node dissection (ALND) can decrease the development of lymphedema, a side effect of ALND. Other purposes of the study include: Comparing the approach of immediate lympha…
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for kids with rare abdominal cancer: drug combo tested
Disease control CompletedThis study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE …
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Targeted drug shows promise for rare bile duct cancer
Disease control CompletedThe primary purpose of the study is to assess the objective response rate (ORR) of E7090 by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 based on independent imaging review (IIR) in participants with unresectable cholangiocarcinoma with FGFR2 gene fusion who failed g…
Phase: PHASE2 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New heart device aims to cut hospital stays for heart failure patients
Disease control OngoingThe OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejec…
Sponsor: Impulse Dynamics • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Smart patch watches new moms for danger signs after C-Section
Disease control CompletedTo estimate the clinical effectiveness of wireless physiologic monitoring of women in the first 24 hours after cesarean delivery at Mbarara Regional Referral Hospital
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
Disease control Recruiting nowThis phase II trial studies the side effects of ONC201 and paclitaxel and how well they work in treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent), or that does not respond to treatment (refrac…
Phase: PHASE2 • Sponsor: Ira Winer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a diabetes drug be the key to slowing Parkinson's?
Disease control CompletedThis study is a clinical trial in patients with Parkinson's disease (PD), of a drug called exenatide, which is already licensed for the treatment of patients with type 2 diabetes. There have been several groups that have confirmed that exenatide has beneficial effects of nerve ce…
Phase: PHASE3 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can more radiation save rectums? new trial aims to find out
Disease control Recruiting nowIn recent years, an increasing number of retrospective and prospective observational studies have indicated that a subset of rectal cancer patients may avoid surgery if they can achieve a complete response to chemoradiotherapy. Prospective trials, including the previous Danish Wa…
Phase: PHASE3 • Sponsor: Vejle Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug acalabrutinib takes on standard combo in untreated CLL
Disease control OngoingThis is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy added to standard drugs may fight aggressive thyroid cancer
Disease control OngoingThis study is being done to see if adding the study drug, cemiplimab, to the standard therapy with dabrafenib and trametinib is an effective treatment against anaplastic thyroid cancer.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Labor drug pause may protect newborns
Disease control CompletedThe purpose of this study is to measure the impact of a discontinuous administration of oxytocin during the active phase of the 1st stage of labor on the neonatal morbidity rate. The investigators hypothesize that discontinuation of oxytocin in the active phase of labor (from 6 …
Phase: PHASE4 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug cocktail shows promise for tough childhood brain cancers
Disease control OngoingThis phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressiv…
Phase: PHASE1, PHASE2 • Sponsor: Pediatric Brain Tumor Consortium • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New pill shows promise against tough lung cancer in early trial
Disease control CompletedThis is a Phase II, open-label, multicenter and multi-cohorts study of PLB1001 administered orally twice daily to locally advanced/metastatic NSCLC patients with c-Met dysregulation.
Phase: PHASE2 • Sponsor: Beijing Pearl Biotechnology Limited Liability Company • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC